Hôpital Foch/Urology Department, Université Versailles St Quentin en Yvelines, 40 rue Worth BP 36, 92151, Suresnes Cedex, France.
Support Care Cancer. 2013 Jun;21(6):1613-20. doi: 10.1007/s00520-012-1705-3. Epub 2013 Jan 9.
This study aimed to explore patient and nurse satisfaction, compliance with best practice, technical feasibility and safety of home infusion of the bisphosphonate zoledronic acid (ZOL).
This was a prospective 1-year survey of home ZOL therapy (4 mg Zometa, 15-min i.v., every 3-4 weeks) in patients with bone metastases secondary to a solid malignancy. A physician questionnaire, nurse satisfaction/feasibility questionnaire and patient satisfaction questionnaire were administered at several time-points.
Physician participation rate was 56.5% (87/154). Physicians enrolled 818 patients visited by 381 predominantly community nurses. Of the 788 case report forms received, 763 met inclusion criteria. Patient characteristics were as follows: median age, 68 years (30-95); M/F, 40/60; ECOG-PS 0 or 1, 78.6%; and primary tumour site, breast (55.2%), prostate (28.4%), lung (7.2%) or other (9.4%). Nurse satisfaction rates were high: organisation of home ZOL therapy, 90.9%; ease of infusion, 96.7%; patient-nurse relationship, 97.5%; and relationship with hospital staff, 73%. Patient satisfaction was also very high (95.3%). The main reasons were quality of the nurse-patient relationship (57.6%), less travel/waiting (68.8%), home environment (52.9%) and less disruption to daily routine (36.6%). ZOL therapy was well tolerated, the discontinuation rate due to adverse events (including deaths whether related to diseases progression or not) was 33.6%. The incidence of osteonecrosis of the jaw was 0.6% and of fractures, 0.2%. Practitioner compliance with best practice was 76.7-83.7% for recommended and/or tolerated dosage, 73% for dental hygiene checks at inclusion and 48-56% thereafter, 66% for pre-infusion hydration, and often undocumented for calcium/vitamin D supplementation.
Home ZOL therapy was well tolerated. Both patient and nurse satisfaction were very high. However, better compliance with best practice should be encouraged.
本研究旨在探讨家庭输注唑来膦酸(ZOL)治疗骨转移患者的患者和护士满意度、最佳实践的依从性、技术可行性和安全性。
这是一项为期 1 年的前瞻性调查,研究对象为接受家庭 ZOL 治疗(4 mg Zometa,静脉注射 15 分钟,每 3-4 周一次)的骨转移患者。在多个时间点进行了医生问卷、护士满意度/可行性问卷和患者满意度问卷调查。
医生参与率为 56.5%(87/154)。医生共招募了 818 名由 381 名主要来自社区的护士照顾的患者。共收到 788 份病例报告表,其中 763 份符合纳入标准。患者特征如下:中位年龄 68 岁(30-95 岁);男女比例为 40/60;ECOG-PS 0 或 1,78.6%;原发肿瘤部位,乳腺癌(55.2%)、前列腺癌(28.4%)、肺癌(7.2%)或其他(9.4%)。护士满意度非常高:家庭 ZOL 治疗的组织安排,90.9%;输注的容易程度,96.7%;护士-患者关系,97.5%;与医院工作人员的关系,73%。患者满意度也非常高(95.3%)。主要原因是护士-患者关系的质量(57.6%)、旅行/等待时间减少(68.8%)、家庭环境(52.9%)和日常活动中断减少(36.6%)。ZOL 治疗耐受性良好,因不良事件(包括无论是否与疾病进展相关的死亡)而停药的发生率为 33.6%。颌骨坏死的发生率为 0.6%,骨折发生率为 0.2%。实践医生对推荐和/或可耐受剂量的最佳实践的依从率为 76.7-83.7%,对纳入时的口腔卫生检查的依从率为 73%,此后为 48-56%,对预输注水化的依从率为 66%,而钙/维生素 D 补充的依从率往往没有记录。
家庭 ZOL 治疗耐受性良好。患者和护士满意度都非常高。然而,应鼓励更好地遵守最佳实践。